Biossil Overview

  • Year Founded
  • 2023

Year Founded

  • Status
  • Private

  • Employees
  • 30

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $153M

  • Investors
  • 13

Biossil General Information

Description

Developer of an artificial intelligence drug discovery platform designed to offer targeted therapies for biologically defined patient sub-populations. The company's platform offers excavate, which combines a data-point multi-omics pipeline with population-scale electronic medical record data to translate disease sub-phenotypes into molecular endotypes defined by interactome-scale disease modules, enabling medical researchers to cut drug repurposing time and bring shelved therapies to trial faster.

Contact Information

Website
www.biossil.co
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 435 Richmond Street West
  • Toronto, Ontario M5V 0N3
  • Canada
Primary Industry
Decision/Risk Analysis
Other Industries
Drug Discovery
Medical Records Systems
Corporate Office
  • 435 Richmond Street West
  • Toronto, Ontario M5V 0N3
  • Canada

Biossil Timeline

202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biossil Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 28-Sep-2026 $153M Completed Clinical Trials - Phase 2
3. Seed Round 20-Apr-2026 Completed Clinical Trials - Phase 2
2. Seed Round 01-Jan-2024 $22M $25.7M Completed Stealth
1. Seed Round 11-Sep-2023 $3.7M $3.7M Completed Stealth
To view Biossil’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Biossil Patents

Biossil Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026224624-A1 Method for treatment or reduction of the incidence of a neural disease Pending 21-Apr-2025
WO-2026163175-A1 Use of gardos channel inhibitors and dosing regimens thereof in the treatment of sickle cell disease Pending 03-Feb-2025
WO-2026163176-A1 Use of gardos channel inhibitors in the treatment of sickle cell disease Pending 03-Feb-2025
WO-2026137073-A1 Adjunct therapy for the treatment of glioblastoma multiforme Pending 23-Dec-2024
WO-2026137071-A1 Combination therapy for the treatment of sickle cell disease Pending 23-Dec-2024 A61P3/00
To view Biossil’s complete patent history, request access »

Biossil Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biossil Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Abu Dhabi Investment Council Sovereign Wealth Fund Minority
DUMAC (Durham) Limited Partner Minority
OpenAI Startup Fund Corporate Venture Capital Minority
137 Ventures Venture Capital Minority
DRI Healthcare Trust Corporation Minority
You’re viewing 5 of 13 investors. Get the full list »

Biossil Investments (4)

Biossil’s most recent deal was a Corporate Asset Purchase with Alligator Bioscience (CD40 Agonist Antibody Mitazalimab) for . The deal was made on 31-Oct-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Alligator Bioscience (CD40 Agonist Antibody Mitazalimab) 31-Oct-2026 Corporate Asset Purchase Buildings and Property
Summit Therapeutics (Ridinilazole Antibiotic Asset) 14-Jul-2026 Corporate Asset Purchase Buildings and Property
Galera Therapeutics (Dismutase Mimetics Portfolio in Toronto, Canada) 22-Oct-2025 Corporate Asset Purchase Buildings and Property
Inventiva Pharma (Global Rights to Odiparcil) 01-Jan-2025 Corporate Asset Purchase Buildings and Property
To view Biossil’s complete investments history, request access »

Biossil FAQs

  • When was Biossil founded?

    Biossil was founded in 2023.

  • Where is Biossil headquartered?

    Biossil is headquartered in Toronto, Canada.

  • What is the size of Biossil?

    Biossil has 30 total employees.

  • What industry is Biossil in?

    Biossil’s primary industry is Decision/Risk Analysis.

  • Is Biossil a private or public company?

    Biossil is a Private company.

  • What is the current valuation of Biossil?

    The current valuation of Biossil is .

  • What is Biossil’s current revenue?

    The current revenue for Biossil is .

  • How much funding has Biossil raised over time?

    Biossil has raised $222M.

  • Who are Biossil’s investors?

    Abu Dhabi Investment Council, DUMAC (Durham), OpenAI Startup Fund, 137 Ventures, and DRI Healthcare Trust are 5 of 13 investors who have invested in Biossil.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process